🇺🇸 FDA

Drug profile · INN

tacrolimus

ADVAGRAF

approved D11AH01
US status
approved
Patents linked
3
News articles
0

Quick answer

tacrolimus (ADVAGRAF) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN tacrolimus
Brand ADVAGRAF
Route TOPICAL
Formulation TABLET, EXTENDED RELEASE
ATC code D11AH01
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 11291657

    Methods of treating inflammatory bowel disease with AMD3100 and Tacrolimus

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10420751

    Methods of treating inflammatory bowel disease with AMD3100 and tacrolimus

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 6187745

    Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus

    Expires Mon Feb 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is tacrolimus?

tacrolimus (ADVAGRAF) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for tacrolimus?

ADVAGRAF is a marketed brand name for tacrolimus. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tacrolimus?

tacrolimus has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.